Methylphenidate cas: 20748-11-2

CAS NO: 20748-11-2
Chemical name: Methylphenidate cas: 20748-11-2 Ritalin and Concerta
Molecular formula: C14H19NO2
Formula weight: 233.31 g/mol
CAS number: 20748-11-2
Description Review
Description
this item was banned in China
we can not make it 


A central nervous system (CNS) stimulant, methylphenidate is well-known under a number of trade names, including Ritalin. It is often used to treat narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD). This page delves further into Methylphenidate, including its chemical properties, mechanism, advantages, safety, and much more.




The treatment of ADHD with methylphenidate, the use of Ritalin, the adverse effects of methylphenidate, the dosage of methylphenidate, and the comparison between MPH and Adderall.

Other products in the same market
Methylphenidate is in competition with other central nervous system stimulants such as:
Similarly, amphetamine-dextroamphetamine (Adderall) is used to treat ADHD.
One of the most powerful derivatives of methylphenidate is called dexmethylphenidate, often known as focalin.
Strattera (atomoxetine): Non-stimulant ADHD therapy.

Benefits to Health
The key advantage of methylphenidate is its ability to improve attention, concentration, and behavioral control in people with ADHD. It also aids in the regulation of sleep cycles in individuals with narcolepsy.

Possible Results
The cognitive abilities and alertness of those using methylphenidate are enhanced since the drug increases brain activity. As a result of this, persons who suffer from attention-deficit/hyperactivity disorder (ADHD) and narcolepsy might see a major improvement in their quality of life.

Product Mechanism
Methylphenidate boosts brain chemicals including dopamine and norepinephrine. In order to improve neurotransmission, this is accomplished by preventing these neurotransmitters from being reabsorbed at the synapse.

Safety
If you take methylphenidate under the care of a doctor, it is usually safe. For the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD), it has received approval from different worldwide regulatory agencies.

Side Effects
Typical side effects may include:

Difficulty sleeping
Loss of interest in food
Headaches
Stomach discomfort
Heart problems, psychological symptoms, and possible dependence are examples of more serious side effects that might happen less often.
Information on Dosage
The dosage of methylphenidate varies depending on age, medical condition, and treatment response. The dosage is typically initiated at a low level and gradually increased to determine the optimal dosage with the least amount of adverse effects.

Warnings
People who have the following conditions should not take methylphenidate:

An extreme sensitivity to the medication
Exploring the origins of drug dependence
Extreme stress or agitation
In conclusion
For many years, methylphenidate has been an important part of treating ADHD and narcolepsy. Several studies have shown its capacity to lessen hyperactivity and increase focus. However, careful monitoring is required to reduce any side effects and ensure that the benefits exceed the dangers.

People Also Ask


Q: What is the mechanism of action of Methylphenidate in treating ADHD?
A: Methylphenidate helps people with ADHD by making them more focused and less reckless and hyperactive. Improving concentration and behavioral regulation, it does this via increasing brain activity of neurotransmitters.

Is methylphenidate addictive?
A: It is true that methylphenidate has the potential to cause dependency and misuse. For this reason, it is administered carefully under close medical supervision, especially in those with a history of drug abuse.

Q: What are the long-term consequences of methylphenidate?
A: The prolonged use of methylphenidate may result in tolerance, psychological dependence, and, in rare instances, cardiovascular complications. To control these risks, healthcare workers must do regular tracking.

Does methylphenidate pose any health risks to children?
Methylphenidate is authorized for ADHD in children over 6. Thorough clinical studies confirmed the drug's safety and effectiveness; nonetheless, it is advised to closely monitor patients for any adverse effects, such as growth suppression.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code